Akrivis Technologies Awarded a Phase I SBIR Contract by the NIH/NCI
Will collaborate with Dana-Farber Cancer Institute and GLG Pharma for the pre-targeted delivery of high payloads of a STAT3 inhibitor specifically to cancer stem cells
Akrivis Technologies, LLC was awarded a Phase I SBIR Contract by the NIH/NCI in September 2014. Akrivis will collaborate with Dana-Farber Cancer Institute and GLG Pharma to develop its proprietary ADAPT™ technology platform for the pre-targeted delivery of high payloads of a small molecule STAT3 inhibitor specifically to cancer stem cells. The focus of this Phase I Small Business Innovation Research Contract is to establish the proof-of-concept for Akrivis’ novel pre-targeted drug delivery approach by which targeting cancer stem cells and delivering a high drug payload are achieved via a 2-step protocol. “This award provides Akrivis with a unique opportunity to generate solid proof-of-concept data with leading oncology investigators and jump starts our efforts in the pre-targeting high payload drug delivery and theranostics areas,” said Joel A. Berniac, Co-Founder, President & CEO of Akrivis Technologies.
For more information visit http://akrivis.com/news/